BACKGROUND: The authors investigated whether stage at diagnosis, cancer treatments, and survival of Asian and Pacific Islander (API) gastric cancer patients in the United States vary by birthplace. METHODS: The authors studied 6454 API and 10,099 non-Hispanic white (NHW) patients diagnosed with gastric cancer from the Surveillance, Epidemiology, and End Results program between 1992 and 2005. In descriptive analyses, stage, receipt of adequate lymph node examination (ALNE), and surgery were compared among US-born APIs, foreign-born (FB) APIs, and NHWs. Multivariate polytomous logistic and proportional hazards regression models were used to assess differences in cancer stage and survival, respectively, adjusted for clinical and demographic factors. RESULTS: As a group, APIs were more likely than NHWs to present with earlier-stage diagnoses and receive surgery and ALNE (P < .001). However, FB (adjusted odds ratios [aOR], 0.79; 95% confidence interval [CI], 0.73-0.86) but not US-born APIs (aOR, 1.05; 95% CI, 0.92-1.20) were significantly more likely to present at earlier stages than NHWs. Compared with NHW patients, FB and US-born APIs were more likely to receive surgery (adjusted risk ratio [aRR], 1.06; 95% CI, 1.03-1.09 and aRR, 1.09; 95% CI, 1.03-1.14, respectively) and ALNE (aRR, 1.29; 95% CI, 1.19-1.41 and aRR, 1.14; 95% CI, 1.00-1.32, respectively). In fully adjusted models, FB (adjusted relative hazard ratios [aHR], 0.86; 95% CI, 0.82-0.90) but not US-born APIs (aHR, 0.96; 95% CI, 0.89-1.04) had more favorable survival than NHWs. CONCLUSIONS: The earlier-stage diagnosis, more complete surgical treatment, and improved survival of Asians and Pacific Islanders with gastric cancer may result from less aggressive tumors or more prompt recognition and thorough evaluation of early symptoms. Further study of these factors could improve outcomes for all patients with gastric cancer. 2009 American Cancer Society.
BACKGROUND: The authors investigated whether stage at diagnosis, cancer treatments, and survival of Asian and Pacific Islander (API) gastric cancerpatients in the United States vary by birthplace. METHODS: The authors studied 6454 API and 10,099 non-Hispanic white (NHW) patients diagnosed with gastric cancer from the Surveillance, Epidemiology, and End Results program between 1992 and 2005. In descriptive analyses, stage, receipt of adequate lymph node examination (ALNE), and surgery were compared among US-born APIs, foreign-born (FB) APIs, and NHWs. Multivariate polytomous logistic and proportional hazards regression models were used to assess differences in cancer stage and survival, respectively, adjusted for clinical and demographic factors. RESULTS: As a group, APIs were more likely than NHWs to present with earlier-stage diagnoses and receive surgery and ALNE (P < .001). However, FB (adjusted odds ratios [aOR], 0.79; 95% confidence interval [CI], 0.73-0.86) but not US-born APIs (aOR, 1.05; 95% CI, 0.92-1.20) were significantly more likely to present at earlier stages than NHWs. Compared with NHW patients, FB and US-born APIs were more likely to receive surgery (adjusted risk ratio [aRR], 1.06; 95% CI, 1.03-1.09 and aRR, 1.09; 95% CI, 1.03-1.14, respectively) and ALNE (aRR, 1.29; 95% CI, 1.19-1.41 and aRR, 1.14; 95% CI, 1.00-1.32, respectively). In fully adjusted models, FB (adjusted relative hazard ratios [aHR], 0.86; 95% CI, 0.82-0.90) but not US-born APIs (aHR, 0.96; 95% CI, 0.89-1.04) had more favorable survival than NHWs. CONCLUSIONS: The earlier-stage diagnosis, more complete surgical treatment, and improved survival of Asians and Pacific Islanders with gastric cancer may result from less aggressive tumors or more prompt recognition and thorough evaluation of early symptoms. Further study of these factors could improve outcomes for all patients with gastric cancer. 2009 American Cancer Society.
Authors: James C Yao; Jennifer F Tseng; Samidha Worah; Kenneth R Hess; Paul F Mansfield; Christopher H Crane; Isac I Schnirer; Satish Reddy; Silvia S Chiang; Azmeena Najam; Christina Yu; Geoffrey G Giacco; Keping Xie; Tsung-Teh Wu; Barry W Feig; Peter W T Pisters; Jaffer A Ajani Journal: J Clin Oncol Date: 2005-05-01 Impact factor: 44.544
Authors: E Bollschweiler; K Boettcher; A H Hoelscher; M Sasako; T Kinoshita; K Maruyama; J R Siewert Journal: Cancer Date: 1993-05-15 Impact factor: 6.860
Authors: Haejin In; Marisa Langdon-Embry; Lauren Gordon; Clyde B Schechter; Judith Wylie-Rosett; Philip E Castle; M Margaret Kemeny; Bruce D Rapkin Journal: J Surg Res Date: 2018-04-03 Impact factor: 2.192
Authors: Signe Smith Nielsen; Yulei He; John Z Ayanian; Scarlett Lin Gomez; Katherine L Kahn; Dee W West; Nancy L Keating Journal: Cancer Date: 2010-07-29 Impact factor: 6.860
Authors: Yufei Chen; Jan Willem Haveman; Christos Apostolou; David K Chang; Neil D Merrett Journal: Gastric Cancer Date: 2014-05-25 Impact factor: 7.370
Authors: René Warschkow; Matthias Baechtold; Kenneth Leung; Bruno M Schmied; Daniel P Nussbaum; Beat Gloor; Dan G Blazer Iii; Mathias Worni Journal: Gastric Cancer Date: 2017-06-23 Impact factor: 7.370
Authors: Daniel D Kirchoff; Gary B Deutsch; Manabu Fujita; David Y Lee; Myung Shin Sim; Ji Hey Lee; Anton J Bilchik Journal: J Gastrointest Surg Date: 2015-08-26 Impact factor: 3.452
Authors: Alexander K Smith; John Z Ayanian; Kenneth E Covinsky; Bruce E Landon; Ellen P McCarthy; Christina C Wee; Michael A Steinman Journal: J Gen Intern Med Date: 2011-02-08 Impact factor: 5.128
Authors: Morteza Bashash; T Greg Hislop; Amil M Shah; Nhu Le; Angela Brooks-Wilson; Chris D Bajdik Journal: BMC Cancer Date: 2011-05-09 Impact factor: 4.430